At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 15 enrolled
Drug / intervention
Ad5-yCD/mutTKSR39rep-hIL12biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer After Definitive Radiotherapy
In Brief
A Phase 1 clinical trial evaluating Ad5-yCD/mutTKSR39rep-hIL12 for Prostate Cancer. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The primary purpose of this phase 1 study is to determine the dose-dependent toxicity and maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy in men with locally recurrent prostate cancer after definitive radiotherapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
First PostedSep 2015
Primary CompletionJun 2019
Study CompletionJan 2024
TodayJul 2026
First PostedSep 21, 2015
Enrollment StartAug 1, 2015
Primary CompletionJun 16, 2019
Study CompletionJan 22, 2024
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.8 years ago
Interventions
Ad5-yCD/mutTKSR39rep-hIL12biological
Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1